An elderly woman with advanced Alzheimer’s disease has shown remarkable, if temporary, improvements in speech, mobility and cognition after receiving high doses of psilocybin-containing mushrooms, according to a case report published in Frontiers in Neuroscience.
The study, led by neuroscientist Marcos Lago and colleagues at the Associação Cruz de Ankh in São Paulo, describes the case of a Japanese-American woman in her 80s who had been living with Alzheimer’s for approximately a decade. For the five years prior to the experimental treatment, she had been largely unable to communicate beyond single words, was chronically incontinent, and depended heavily on carers for basic daily activities.
Researchers administered five grams of psilocybin-containing mushrooms of the Enigma strain, a quantity known in recreational circles as a “heroic dose” and considerably larger than the amounts typically used in clinical trials. The acute effects were intense: the patient experienced profuse sweating, suspected hyperthermia, and entered a prolonged sleep-like state.
What happened roughly 19 hours later surprised everyone involved. The woman woke spontaneously and began talking to herself in full autobiographical sentences, continuing for several hours. In the days that followed, she regained bladder control, walked and dressed herself independently, maintained eye contact, smiled reciprocally, and engaged in sustained conversation.
The researchers noted that the restoration of urinary continence was particularly striking given that it had been absent for more than five years. Maintaining continence requires integrated function across several brain networks, including the fronto-insular system, which is heavily affected by Alzheimer’s pathology.
A second supervised session a month later, using a lower three-gram dose, produced further gains. On this occasion the patient remained awake throughout, described vivid and emotionally positive imagery including surfing with her son on a peaceful island, showed spontaneous humour, and moved with noticeably greater agility. Unprompted, she remarked: “It is pleasant to come here.”
The authors are careful to emphasise what their findings cannot establish. The study involved a single patient, included no control group, no standardised cognitive assessments, no brain imaging, and no electrophysiological monitoring. The woman’s Alzheimer’s diagnosis was made clinically rather than confirmed through modern biomarkers, meaning other neurodegenerative contributions cannot be entirely ruled out. Natural fluctuations in dementia symptoms are also well documented, making it impossible to attribute the improvements definitively to psilocybin.
“The findings should not be interpreted as a reversal of Alzheimer’s pathology,” the authors write. Instead, they suggest that dormant functional capacity may persist even in the later stages of neurodegeneration, and that under the right neurological conditions, some of that capacity might temporarily resurface.
The proposed mechanism draws on existing research showing that psilocybin, through its action on serotonin receptors, can increase global brain connectivity, promote neural plasticity, and temporarily disrupt the rigid network segregation that characterises both healthy and diseased brains. Whether those effects can meaningfully interact with the neural damage wrought by Alzheimer’s remains an open and important question.
Interest in psilocybin as a potential therapy for dementia-related conditions has been building gradually. Researchers have explored its capacity to reduce depression and anxiety in people with early-stage Alzheimer’s, and at least one pilot trial examining its effects on mild cognitive impairment is already under way. A recent survey of more than 3,000 American adults found that those who had used a hallucinogen in the past year reported fewer depressive symptoms and showed more favourable changes in certain brain functions.
Outside experts have responded to the Brazilian case report with measured interest. Courtney Kloske from the Alzheimer’s Association stressed that much larger and more rigorous studies are needed before any conclusions about safety or effectiveness can be drawn. Fox News medical analyst Dr Marc Siegel described himself as sceptical of a single temporary case, while acknowledging that psilocybin might have some value in carefully controlled settings.
Dementia research has a sobering track record: many promising treatments have collapsed at the clinical trial stage. Psilocybin’s path from a single extraordinary case report to an approved therapy, if it gets there at all, will be long and demanding. For now, the story of one woman briefly rediscovering her voice, her memories, and her sense of humour offers something researchers rarely encounter in late-stage Alzheimer’s: a reason to look more closely.
